Lenvatinib Avansor: Uses, Dosage & Side Effects

What Is Lenvatinib Avansor and What Is It Used For?

Lenvatinib Avansor contains the active substance lenvatinib (as lenvatinib mesilate), a small-molecule oral multikinase inhibitor developed to target multiple receptor tyrosine kinases (RTKs) that drive tumor angiogenesis, tumor cell proliferation, and the tumor microenvironment. As a targeted anticancer therapy, lenvatinib represents a significant advancement in the treatment of several difficult-to-treat malignancies by simultaneously inhibiting multiple signaling pathways that tumors rely on for growth and survival.

The mechanism of action of lenvatinib involves selective inhibition of the kinase activities of vascular endothelial growth factor receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptors FGFR1 through FGFR4, platelet-derived growth factor receptor alpha (PDGFRα), KIT (stem cell factor receptor), and the RET proto-oncogene. These receptor tyrosine kinases play critical roles in the formation of new blood vessels (angiogenesis) that supply tumors with oxygen and nutrients, as well as in the direct proliferation and survival of tumor cells. By inhibiting these targets simultaneously, lenvatinib disrupts the tumor vasculature and directly impairs tumor cell growth, leading to tumor shrinkage or stabilization of disease progression.

The inhibition of VEGFR signaling is particularly important in lenvatinib's anticancer activity. VEGF-mediated angiogenesis is one of the hallmarks of cancer, as tumors must establish their own blood supply to grow beyond a few millimeters in size. Lenvatinib's additional inhibition of FGFR pathways is clinically significant because FGF signaling has been identified as a mechanism of resistance to anti-VEGF therapies. By simultaneously blocking both VEGFR and FGFR pathways, lenvatinib may overcome or delay the development of such resistance. The inhibition of PDGFRα further contributes to the anti-angiogenic effect by targeting pericytes, the cells that stabilize newly formed blood vessels.

Lenvatinib Avansor is approved for the following clinical indications, either as monotherapy or in combination with other anticancer agents:

• Differentiated thyroid cancer (DTC): Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, or Hürthle cell) that is refractory to radioactive iodine (RAI) therapy. The pivotal SELECT trial (Study of [E7080] LEnvatinib in Differentiated Cancer of the Thyroid) demonstrated a significant improvement in progression-free survival (PFS) of 18.3 months with lenvatinib compared to 3.6 months with placebo (hazard ratio 0.21; p<0.001). The objective response rate was 64.8% with lenvatinib versus 1.5% with placebo.
• Hepatocellular carcinoma (HCC): Lenvatinib is approved as a first-line treatment for adult patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy. The REFLECT trial demonstrated that lenvatinib was non-inferior to sorafenib for overall survival (median OS: 13.6 months vs. 12.3 months), with statistically significant improvements in PFS (7.4 vs. 3.7 months), time to progression (8.9 vs. 3.7 months), and objective response rate (24.1% vs. 9.2% per mRECIST criteria).
• Renal cell carcinoma (RCC): Lenvatinib in combination with everolimus is approved for the treatment of adult patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. The phase II Study 205 demonstrated a significant improvement in PFS (14.6 months for the combination vs. 5.5 months for everolimus alone; HR 0.40; p=0.0005).
• Endometrial carcinoma (EC): Lenvatinib in combination with pembrolizumab is approved for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation. The Study 309/KEYNOTE-775 trial demonstrated significant improvements in both PFS and overall survival compared to chemotherapy.

Lenvatinib was originally developed and marketed by Eisai under the brand name Lenvima. Lenvatinib Avansor is a generic formulation that contains the same active substance and has been approved based on demonstration of bioequivalence to the reference product, ensuring the same therapeutic effect, safety profile, and quality standards. Generic medicines undergo rigorous evaluation by regulatory authorities to confirm they meet all applicable requirements before being authorized for use.

What Should You Know Before Taking Lenvatinib Avansor?

Contraindications

The primary contraindication for Lenvatinib Avansor is hypersensitivity to lenvatinib mesilate or to any of the excipients contained in the formulation. If you have a known allergy to lenvatinib or any of the inactive ingredients in the capsule, you must not take this medicine. Signs of hypersensitivity may include skin rash, itching, swelling, difficulty breathing, or anaphylaxis. If you experience any of these symptoms, seek immediate medical attention.

In addition to hypersensitivity, Lenvatinib Avansor is contraindicated during pregnancy and in women of childbearing potential who are not using effective contraception, due to the established embryo-fetal toxicity of the drug. The drug must also be used with extreme caution in patients with severe hepatic impairment (Child-Pugh C), as safety and efficacy have not been adequately established in this population, and dose adjustments are required for patients with moderate hepatic impairment. Breastfeeding must be discontinued during treatment due to the potential for serious adverse reactions in the breastfed infant.

Warnings and Precautions

Lenvatinib carries several important warnings and precautions that patients and healthcare providers must be aware of. These reflect the drug's potent pharmacological activity and its effects on multiple organ systems:

• Hypertension: High blood pressure is one of the most common and clinically significant adverse effects of lenvatinib, occurring in up to 73% of patients in clinical trials. Blood pressure must be well controlled before initiating treatment. Regular monitoring is essential, and antihypertensive medications should be started or adjusted as needed. Severe hypertension (grade 3 or higher) may require dose reduction, interruption, or permanent discontinuation of lenvatinib.
• Cardiac dysfunction: Decreased left ventricular ejection fraction and cardiac failure have been reported. Patients should be monitored for clinical signs and symptoms of cardiac dysfunction. Lenvatinib should be used with caution in patients with a history of heart failure, and cardiac function should be assessed before and during treatment.
• Arterial thromboembolic events: Myocardial infarction, cerebrovascular accident (stroke), and transient ischemic attack have been reported. Lenvatinib has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months and should be used with caution in such patients.
• Hepatotoxicity: Liver injury, including cases of hepatic failure and death, has occurred. Liver function tests should be performed before starting treatment, at least every 2 weeks for the first 2 months, and monthly thereafter. Dose modifications may be necessary based on the severity of liver enzyme elevations.
• Renal failure and impairment: Renal events, including renal failure, have been reported. Kidney function should be monitored before and during treatment. Dose reduction is required in patients with severe renal impairment (creatinine clearance <30 mL/min).
• Proteinuria: Protein in the urine has been reported in a significant proportion of patients. Urine protein should be monitored regularly. If 24-hour urine protein is ≥2 g, dose modification may be required. Nephrotic syndrome has occurred rarely and warrants permanent discontinuation.
• Hemorrhagic events: Serious and sometimes fatal bleeding events, including cerebral, pulmonary, and gastrointestinal hemorrhage, have been reported. Lenvatinib should be used with caution in patients at risk of bleeding, and the drug should be discontinued in patients with grade 3 or higher hemorrhage.
• Gastrointestinal perforation and fistula: Cases of GI perforation and fistula formation have been reported. Patients should be monitored for symptoms such as severe abdominal pain. Lenvatinib should be permanently discontinued in patients who develop GI perforation or life-threatening fistula.
• QT prolongation: QT/QTc interval prolongation has been observed at higher rates with lenvatinib compared to placebo. ECG monitoring should be performed in patients with congenital long QT syndrome, heart failure, bradycardia, or those taking medications known to prolong the QT interval. Electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia) should be corrected before starting treatment.
• Posterior reversible encephalopathy syndrome (PRES): PRES (also known as reversible posterior leukoencephalopathy syndrome) has been reported rarely. Symptoms include headache, seizures, visual disturbances, confusion, and altered mental function. If PRES is diagnosed, lenvatinib should be withheld and appropriate medical management initiated.

Pregnancy and Breastfeeding

Lenvatinib Avansor must not be used during pregnancy. Based on its mechanism of action (inhibition of VEGFR and other receptor tyrosine kinases involved in embryonic development) and findings from animal reproduction studies, lenvatinib is expected to cause embryo-fetal harm when administered during pregnancy. Animal studies demonstrated embryotoxicity and teratogenicity at clinically relevant exposures, including skeletal abnormalities, fetal growth retardation, and increased embryo-fetal lethality. There are no adequate and well-controlled studies of lenvatinib in pregnant women.

Women of childbearing potential must use highly effective methods of contraception during treatment with lenvatinib and for at least 30 days after the last dose. If a patient becomes pregnant while taking lenvatinib, she must be informed of the potential hazard to the fetus and the drug should be discontinued. A pregnancy test should be performed before starting treatment. Male patients with female partners of childbearing potential should use effective contraception during treatment and for at least 1 week after the last dose.

It is not known whether lenvatinib or its metabolites are excreted in human breast milk. However, given the drug's lipophilicity and low molecular weight, excretion into breast milk is considered likely. Because of the potential for serious adverse reactions in breastfed infants, breastfeeding must be discontinued during treatment with lenvatinib and for at least 1 week after the last dose. The decision to discontinue breastfeeding or to discontinue lenvatinib should take into account the importance of the drug to the mother's cancer treatment.

Fertility

The effect of lenvatinib on human fertility has not been studied. However, animal studies have shown effects on male and female fertility. In rats, lenvatinib was shown to impair female fertility at doses below the recommended human dose, with effects including decreased numbers of corpora lutea, implantation sites, and viable fetuses. Testicular toxicity was also observed in repeat-dose toxicity studies in animals. Patients of reproductive age should be counseled about the potential risks to fertility and may wish to consider fertility preservation options before starting treatment.

Impaired Wound Healing

Impaired wound healing is a class effect of drugs that inhibit VEGF signaling. Lenvatinib has the potential to adversely affect wound healing. Treatment with lenvatinib should be interrupted for at least 6 days prior to elective surgery. It should not be resumed for at least 2 weeks following major surgical procedures and until adequate wound healing is established. The safety of resumption of lenvatinib after resolution of wound healing complications has not been established.

How Does Lenvatinib Avansor Interact with Other Drugs?

Lenvatinib undergoes metabolism primarily through CYP3A4 (the cytochrome P450 3A4 enzyme) and aldehyde oxidase (AO), with minor contributions from other enzymatic pathways. Understanding the drug interaction profile of lenvatinib is essential for safe prescribing, as many cancer patients receive multiple concomitant medications for pain management, infection prophylaxis, supportive care, and management of comorbid conditions.

In vitro studies have shown that lenvatinib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but not a significant inhibitor or inducer of CYP enzymes at clinically relevant concentrations. Lenvatinib does not significantly inhibit P-gp, BCRP, organic anion transporting polypeptides (OATP1B1, OATP1B3), organic anion transporters (OAT1, OAT3), organic cation transporter (OCT2), multidrug and toxin extrusion proteins (MATE1, MATE2-K), or bile salt export pump (BSEP) at therapeutic concentrations.

The following table summarizes the key known and potential drug interactions with lenvatinib:

Interaction with Food

Lenvatinib can be taken with or without food. Food does not significantly affect the overall extent of absorption (AUC) of lenvatinib, although it may delay the rate of absorption (Tmax increased by approximately 2 hours when taken with food). This delay in absorption is not considered clinically significant. For consistency, patients are generally advised to take lenvatinib at approximately the same time each day, either consistently with food or consistently without food.

Grapefruit and grapefruit juice are known CYP3A4 inhibitors and may theoretically increase lenvatinib exposure. Although the clinical significance of this interaction has not been specifically studied, patients may wish to avoid regular consumption of grapefruit products while taking lenvatinib, as a precautionary measure.

Combination Therapy Considerations

When lenvatinib is used in combination with everolimus (for renal cell carcinoma) or pembrolizumab (for endometrial carcinoma), the potential for drug interactions is expanded. Everolimus is both a substrate and inhibitor of CYP3A4 and P-gp, and may affect lenvatinib exposure. Pembrolizumab, as a monoclonal antibody, does not have traditional pharmacokinetic drug interactions but can cause immune-mediated adverse reactions that may overlap with or exacerbate lenvatinib toxicities. In combination regimens, patients should be monitored for additive or synergistic adverse effects, and dose modifications of each agent should be managed independently according to their respective prescribing information.

What Is the Correct Dosage of Lenvatinib Avansor?

Treatment with Lenvatinib Avansor should be initiated and supervised by a physician experienced in the management of cancer therapy. The dose depends on the specific indication being treated, and in some cases, on the patient's body weight and organ function. Lenvatinib capsules are taken orally once daily, at approximately the same time each day, with or without food. The capsules should be swallowed whole with water.

Adults

For adult patients with normal organ function, the recommended starting doses are as outlined in the table above. Dose adjustments may be necessary based on individual tolerability and the occurrence of adverse reactions. Lenvatinib dose reductions follow a stepwise approach, with each dose level reduction typically being 4 mg less than the current dose. For example, in DTC patients starting at 24 mg, the first dose reduction would be to 20 mg, the second to 14 mg, and the third to 10 mg. If a dose below the minimum recommended level cannot be tolerated, treatment should be permanently discontinued.

For patients with hepatic impairment, dose adjustments are recommended. In mild hepatic impairment (Child-Pugh A), no dose adjustment is required. In moderate hepatic impairment (Child-Pugh B), a dose reduction may be considered based on the specific indication. In severe hepatic impairment (Child-Pugh C), the recommended dose is 14 mg once daily for DTC, and clinical data are limited for other indications. For patients with renal impairment, no dose adjustment is generally required for mild or moderate renal impairment. In severe renal impairment (creatinine clearance <30 mL/min), a dose adjustment to 14 mg once daily for DTC is recommended, with appropriate reductions for other indications.

Children

The safety and efficacy of lenvatinib in children and adolescents below 18 years of age have not been established. There are currently no data from clinical trials in pediatric patients for any of the approved indications. Therefore, Lenvatinib Avansor is not recommended for use in patients under 18 years of age. Pediatric oncology research involving lenvatinib may be ongoing, and any future recommendations will depend on the results of dedicated clinical studies in this age group.

Elderly

No initial dose adjustment is required for elderly patients (≥65 years). However, clinical experience in patients aged 75 years and older is more limited. Elderly patients may be more susceptible to certain adverse effects of lenvatinib, including hypertension, fatigue, decreased appetite, and dehydration. Close monitoring and proactive management of adverse effects is particularly important in this population. Dose modifications should be made as needed based on individual tolerability, following the same stepwise reduction guidelines used for younger adults.

Missed Dose

If a dose is missed and cannot be taken within 12 hours of the usual time, that dose should be skipped, and the next dose should be taken at the regular scheduled time. Patients should not take a double dose to make up for a missed dose. Taking a double dose could increase the risk of adverse effects, particularly hypertension and gastrointestinal toxicity. If vomiting occurs after taking a dose, the patient should not take an additional dose but should wait until the next scheduled dose.

Overdose

There is no specific antidote for lenvatinib overdose. In the event of suspected overdose, the patient should be monitored closely and given appropriate supportive care. Due to the high plasma protein binding of lenvatinib (approximately 98–99%), hemodialysis is not expected to be effective in removing the drug from the circulation. Signs and symptoms of overdose are likely to be an exaggeration of the known adverse effects of lenvatinib, including severe hypertension, gastrointestinal toxicity, bleeding, and organ dysfunction. In a clinical trial, accidental overdoses at approximately twice the recommended daily dose were reported. The most common adverse reactions in these cases were hypertension, nausea, diarrhea, and fatigue. Patients should be managed with supportive measures and close monitoring in an appropriate clinical setting.

What Are the Side Effects of Lenvatinib Avansor?

Like all medicines, Lenvatinib Avansor can cause side effects, although not everybody gets them. As a multikinase inhibitor with broad pharmacological activity, lenvatinib has a well-characterized safety profile that reflects its effects on multiple biological pathways. Many of the adverse reactions associated with lenvatinib are related to its anti-angiogenic mechanism of action and are common to the class of VEGFR-targeting therapies. The frequency and severity of side effects may vary depending on the indication, dose, and combination therapy used.

Clinical trials across all approved indications have established the following frequency-based profile of adverse reactions. Understanding this profile is important for both patients and healthcare providers, as early recognition and management of side effects is essential for maintaining treatment compliance and optimizing therapeutic outcomes. Dose modifications (reductions, interruptions, or discontinuation) were required in a significant proportion of patients across clinical trials.

Many of the very common side effects, while frequent, are typically mild to moderate in severity and can be managed with supportive care, dose interruptions, or dose reductions. Hypertension, for example, is manageable with antihypertensive therapy in most patients. Diarrhea can usually be controlled with loperamide and dietary modifications. Stomatitis may be managed with oral hygiene measures and topical treatments. Fatigue is one of the more challenging side effects to manage and may require dose reduction if it significantly impairs the patient's quality of life.

Serious adverse reactions require prompt medical attention and may necessitate permanent discontinuation of lenvatinib. These include hepatotoxicity with grade 3 or higher liver enzyme elevations, arterial thromboembolic events, grade 3 or higher hemorrhage, gastrointestinal perforation, nephrotic syndrome, and PRES. Patients should be educated about the signs and symptoms of these serious adverse reactions and instructed to contact their healthcare provider immediately if they occur.

How Should You Store Lenvatinib Avansor?

Proper storage of Lenvatinib Avansor is essential to maintain the quality, safety, and efficacy of the medication throughout its shelf life. As an oral anticancer medication, lenvatinib capsules contain a precisely formulated combination of active and inactive ingredients that can be affected by environmental conditions such as temperature, humidity, and light exposure.

Store the capsules at or below 25°C (77°F). Brief excursions up to 30°C (86°F) may be permitted, but prolonged storage above 25°C should be avoided. Keep the capsules in the original blister packaging until the time of use to protect them from moisture. Do not transfer the capsules to other containers such as pill boxes or organizers for extended periods, as this may expose them to moisture that could affect the capsule shell integrity and drug stability.

Do not use Lenvatinib Avansor after the expiry date printed on the carton and blister after "EXP." The expiry date refers to the last day of that month. Keep this medicine out of the sight and reach of children, preferably in a locked cabinet or high shelf. Given the serious nature of this medication, accidental ingestion by children or other household members could have significant health consequences.

Do not throw away any medicines via wastewater or household waste. Anticancer medicines require special disposal procedures to protect the environment and prevent accidental exposure. Ask your pharmacist how to dispose of medicines you no longer use or that have expired. Unused or expired lenvatinib capsules should be returned to a pharmacy for safe disposal in accordance with local regulations for cytotoxic drug waste.

What Does Lenvatinib Avansor Contain?

Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients. The following provides a detailed breakdown of the active and inactive components of Lenvatinib Avansor capsules.

Active substance: Each hard capsule contains 4 mg of lenvatinib (equivalent to 4.90 mg of lenvatinib mesilate). Lenvatinib mesilate is the salt form of the drug that provides optimal stability and bioavailability. The mesilate salt is a white to slightly yellowish powder that is slightly soluble in water.

Capsule contents (excipients): The typical excipients in a lenvatinib capsule formulation include calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc. These inactive ingredients serve specific functions: calcium carbonate and mannitol act as fillers to provide the necessary bulk, microcrystalline cellulose aids in binding, hydroxypropylcellulose serves as a disintegrant to ensure the capsule dissolves properly after ingestion, and talc acts as a lubricant to facilitate the manufacturing process.

Capsule shell: The hard capsule shell is typically composed of hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171, used as an opacifier), and iron oxide yellow (E172, used as a colorant). The capsule shell may also contain gellan gum and potassium acetate. The specific colors and markings on the capsule may vary and are used to identify the strength and distinguish it from other dosage strengths.

If you have a known allergy or intolerance to any of the excipients listed above, inform your doctor or pharmacist before starting treatment. In particular, patients with rare hereditary problems of fructose intolerance (if mannitol-containing) should take this into consideration. The capsules do not contain lactose, gluten, or sucrose.